Online inquiry

IVTScrip™ mRNA-Anti-GP, c2G4-N(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ4978MR)

This product GTTS-WQ4978MR is a type of mRNA modified with 5-Methyl-CTP & Pseudo-UTP, which ecodes the monoclonal antibody that targets GP gene. The antibody can be applied in Ebola virus infection research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Chimeric
RefSeq NP_066246.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 911829
UniProt ID Q05320
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-GP, c2G4-N(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ4978MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ1873MR IVTScrip™ mRNA-Anti-CTLA4, AGEN1884(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA AGEN1884
GTTS-WQ4200MR IVTScrip™ mRNA-Anti-IL2RA, BIIB019(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BIIB019
GTTS-WQ6567MR IVTScrip™ mRNA-Anti-EGFR, DC-1630423(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA DC-1630423
GTTS-WQ12808MR IVTScrip™ mRNA-Anti-MASP2, OMS721(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA OMS721
GTTS-WQ13599MR IVTScrip™ mRNA-Anti-APP, R1450(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA R1450
GTTS-WQ11083MR IVTScrip™ mRNA-Anti-CSF1, MCS-110(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MCS-110
GTTS-WQ3788MR IVTScrip™ mRNA-Anti-Factor VIIa substitute, BAY-86-6150(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA BAY-86-6150
GTTS-WQ8935MR IVTScrip™ mRNA-Anti-IL1B, IL-1 Trap(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA IL-1 Trap
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW